AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression
Public ClinicalTrials.gov record NCT03078322. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Double-Blind, Placebo-Controlled, Phase 2 Trial to Test Efficacy and Safety of AV-101 (L-4-chlorokynurenine) as Adjunct to Current Antidepressant Therapy in Patients With Major Depressive Disorder (the ELEVATE Study)
Study identification
- NCT ID
- NCT03078322
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- VistaGen Therapeutics, Inc.
- Industry
- Enrollment
- 180 participants
Conditions and interventions
Conditions
Interventions
- AV-101 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 4, 2018
- Primary completion
- Sep 30, 2019
- Completion
- Sep 30, 2019
- Last update posted
- Oct 8, 2019
2018 – 2019
United States locations
- U.S. sites
- 22
- U.S. states
- 13
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| VistaGen Investigational Site | Garden Grove | California | 92845 | — |
| VistaGen Investigational Site | Los Angeles | California | 90024 | — |
| VistaGen Investigational Site | National City | California | 91950 | — |
| VistaGen Investigational Site | Oakland | California | 94607 | — |
| VistaGen Investigational Site | San Diego | California | 92103 | — |
| VistaGen Investigational Site | Temecula | California | 92591 | — |
| VistaGen Investigational Site | Fort Myers | Florida | 33912 | — |
| VistaGen Investigational Site | Jacksonville | Florida | 32256 | — |
| VistaGen Investigational Site | Atlanta | Georgia | 30331 | — |
| VistaGen Investigational Site | Augusta | Georgia | 30912 | — |
| VistaGen Investigational Site | Hoffman Estates | Illinois | 60169 | — |
| VistaGen Investigational Site | Lake Charles | Louisiana | 70629 | — |
| VistaGen Investigational Site | Gaithersburg | Maryland | 20877 | — |
| VistaGen Investigational Site | St Louis | Missouri | 63141 | — |
| VistaGen Investigational Site | New York | New York | 10128 | — |
| VistaGen Investigational Site | Rochester | New York | 14618 | — |
| VistaGen Investigational Site | Dayton | Ohio | 45417 | — |
| VistaGen Investigational Site | Oklahoma City | Oklahoma | 73112 | — |
| VistaGen Investigational Site | Media | Pennsylvania | 19063 | — |
| VistaGen Investigational Site | Houston | Texas | 77030 | — |
| VistaGen Investigational Site | Houston | Texas | 77058 | — |
| VistaGen Investigational Site | Bellevue | Washington | 98007 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03078322, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 8, 2019 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03078322 live on ClinicalTrials.gov.